We then compared the ex vivo activity of TP-0903 and gilteritinib in 3 human primary AML samples with FLT3-ITD and co-occurring RAS pathway (NRAS, KRAS, and PTPN11) mutations. Here, KRAS is linked to acute myeloid leukemia.